Innoxel Lifesciences commences commercial supply to US market

Bharat Parenterals announced that its subsidiary, Innoxel Lifesciences (Innoxel), has commenced commercial supply to the United States. The first product manufactured by Innoxel under a contract manufacturing (CMO) arrangement was launched in the U.S. market by its sponsor partner on 20 October 2026, the auspicious day of Vijayadashami.

The sponsor selected Innoxel as its manufacturing partner for the product, and Auxilla Pharmaceuticals and Research LLP served as the development partner.

The product is made at Innoxel's finished dosage facility in Vadodara, Gujarat, which received an Establishment Inspection Report (EIR) from the U.S. FDA in July 2025 and an EU-GMP certificate covering all four of its lines in March 2026. The identity of the sponsor and details of the product are not being disclosed in line with confidentiality obligations.

The launch is the first of the two CMO products the Company expects to commercialise in FY27. It also changes the make-up of Innoxel's revenue. All of Innoxel's FY26 revenue of Rs 72.4 crore came from licensing, of which Rs 17.1 crore was upfront and Rs 55.3 crore milestone-linked. Commercial supply adds a recurring line on top of that base, earned on every batch shipped to partners selling in the U.S.

Innoxel signed 23 deals in FY26, seven of them out-licensing and sixteen CMO/CDO, taking its total since inception to 48. It works with 19 active partners: eight in the United States, six in the European Union and five in India, all of whom are working on products for regulated markets.